Association of BTRC rs10883617 with Survival Outcomes in Surgically Resected Non-Small Cell Lung Cancer
Authors:
- Seongwon ShinSSSeongwon Shin
- Chi Young JungCJChi Young Jung
- Mi Jeong HongMHMi Jeong Hong
- Jang Hyuck LeeJLJang Hyuck Lee
- Won Kee LeeWLWon Kee Lee
- Ji Eun ParkJPJi Eun Park
- Yong Hoon LeeYLYong Hoon Lee
- Hyewon SeoHSHyewon Seo
- Jaehee LeeJLJaehee Lee
- Shin Yup LeeSLShin Yup Lee
- Sun Ha ChoiSCSun Ha Choi
- Seung Ick ChaSCSeung Ick Cha
Open Access
Abstract
Background/Objectives: Genetic variation in components of the ubiquitin–proteasome system may contribute to cancer progression and clinical outcomes. This study investigated whether potentially functional variants in E3 ubiquitin ligase-related genes are associated with survival outcomes after surgical resection of non-small cell lung cancer (NSCLC). Methods: The study included 744 Korean patients with stage I–IIIA NSCLC, divided into discovery and validation cohorts. Fifty-one potentially functional single-nucleotide polymorphisms in E3 ubiquitin ligase-related genes were evaluated for associations with overall survival (OS) and disease-free survival (DFS). Results: Among the polymorphisms examined, BTRC rs10883617 T>C was significantly associated with DFS in the validation cohort, whereas the association with OS showed a concordant trend but did not reach statistical significance. In the combined cohort, carriers of at least one C allele had significantly better OS (HR = 0.55, 95% CI = 0.34–0.90, p = 0.02) and DFS (HR = 0.64, 95% CI = 0.46–0.89, p = 0.01) than patients with the TT genotype. The C allele demonstrated significantly lower promoter activity than the T allele in A549 and H1299 lung cancer cell lines (both p < 0.01). BTRC mRNA expression was significantly higher in tumor tissues than in paired non-neoplastic tissues (p < 0.001), but did not differ by genotype. Conclusions: Collectively, BTRC rs10883617 T>C was associated with favorable survival outcomes and allele-specific promoter activity in surgically resected NSCLC. However, its effect on endogenous BTRC expression remains unconfirmed in this patient population. Independent external validation and further mechanistic studies are warranted.Keywords
Funding Information
- National Research Foundation of Korea (NRF-2020R1A2C1011917)
- National Research Foundation of Korea (RS-2025-25417579)
This publication has 22 references indexed in Scilit:
- Structural insights into substrate recognition by the SOCS2 E3 ubiquitin ligaseNature Communications, 2019
- The Eukaryotic Proteome Is Shaped by E3 Ubiquitin Ligases Targeting C-Terminal DegronsCell, 2018
- Ubiquitin ligases in oncogenic transformation and cancer therapyNature Reviews Cancer, 2017
- Tracking the Evolution of Non–Small-Cell Lung CancerNew England Journal of Medicine, 2017
- The β-TrCP-FBXW2-SKP2 axis regulates lung cancer cell growth with FBXW2 acting as a tumour suppressorNature Communications, 2017
- Copy number variation of E3 ubiquitin ligase genes in peripheral blood leukocyte and colorectal cancerScientific Reports, 2016
- Relevance of Sp Binding Site Polymorphism inWWOXfor Treatment Outcome in Pancreatic CancerJNCI: Journal of the National Cancer Institute, 2016
- Ubiquitination in disease pathogenesis and treatmentNature Medicine, 2014
- Degradation of Cdc25A by β-TrCP during S phase and in response to DNA damageNature, 2003
- Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomasNature Medicine, 1997